M. Kulyk & Associates LLC Buys 8,129 Shares of Becton, Dickinson and Company (NYSE:BDX)

M. Kulyk & Associates LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 38.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,442 shares of the medical instruments supplier’s stock after buying an additional 8,129 shares during the quarter. Becton, Dickinson and Company accounts for about 1.4% of M. Kulyk & Associates LLC’s investment portfolio, making the stock its 24th largest position. M. Kulyk & Associates LLC’s holdings in Becton, Dickinson and Company were worth $6,680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of BDX. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $25,000. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company in the 4th quarter valued at $29,000. Ashton Thomas Securities LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter valued at $33,000. Tompkins Financial Corp raised its position in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Finally, Kennebec Savings Bank bought a new position in Becton, Dickinson and Company in the 3rd quarter valued at $46,000. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In related news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares of the company’s stock, valued at $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,061 shares of company stock valued at $1,379,521 over the last three months. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.8 %

BDX stock opened at $229.51 on Friday. The company has a market cap of $65.90 billion, a P/E ratio of 38.12, a PEG ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The business has a fifty day moving average of $232.98 and a 200-day moving average of $232.72.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Barclays lifted their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.